On Friday, Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.71 which represents no change from the prior close of of $0.71. The stock opened at $0.72 and touched a low of $0.7 during ...
Hosted on MSN3d
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialOcugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...
On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...
MyChesCo on MSN4d
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaOcugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for ...
Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback